Axcellant at EANM 2025: What We Brought Back from Barcelona

1. paź 24, 2025

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s safe to say the momentum in nuclear medicine is stronger than ever.

EANM remains one of the most important meetings in our calendar, offering a clear lens into the future of imaging-driven research and theranostics. This year’s edition was no exception — packed with promising technologies, practical discussions, and bold new directions for clinical application.

Among the key topics that caught our attention:

• Theranostics is evolving rapidly, with growing interest in moving from β‑ to α‑emitters such as Ac‑225‑PSMA and Ac‑DOTATATE. These approaches show real potential to deliver deeper tumor control with reduced toxicity.
• FAPI-based radiopharmaceuticals are gaining ground across multiple areas, including oncology, cardiac remodeling, and chronic inflammation — reinforcing their versatility beyond cancer alone.
• CXCR4-targeted theranostics served as another strong example of how nuclear medicine is continuing to blur the lines between diagnostics and precision therapy.
• AI in imaging workflows is no longer theoretical — with tools for PET/CT segmentation and automated dosimetry now offering practical ways to improve consistency and efficiency in clinical trials.

EANM 2025 only reaffirmed that nuclear medicine is not just a focus area for Axcellant — it’s a field where our operational and regulatory expertise can drive real value. Read more about the conference here.